Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the sickle cell disease treatment market grown over the years?

The sickle cell disease treatment market has grown rapidly, with projections indicating an increase from $2.95 billion in 2024 to $3.54 billion in 2025 at a CAGR of 19.7%. The expansion has been fueled by better disease understanding, advancements in blood transfusions, pain management strategies, and hydroxyurea therapy.

What Is the forecasted market size and growth rate for the sickle cell disease treatment market?

The sickle cell disease treatment market is set for rapid expansion, projected to hit $6.8 billion in 2029 with a CAGR of 17.7%. Factors fueling this growth include gene editing and therapy, new drug development, telemedicine, and global health initiatives. Trends include the rise of curative therapies, pain management alternatives, global collaborations, and increased patient advocacy.

Get your sickle cell disease treatment market report here!

https://www.thebusinessresearchcompany.com/report/sickle-cell-disease-treatment-global-market-report

What are the major factors driving growth in the sickle cell disease treatment market?

The expected surge in blood transfusion requirements is poised to spur the expansion of the market for sickle cell disease treatments. Blood transfusion, a medical practice involving the transfer of blood or blood products from a donor to a recipient, plays an integral role in managing sickle cell disease. This procedure aids in enhancing the oxygen-carrying ability of blood and alleviates complications tied to vaso-occlusion. As reported by the Mid-Atlantic Long-Term Care, a company in the USA that offers specialist 24-hour triage on-call assistance, around 29,000 units of red blood cells, 5,000 units of platelets, and 6,500 units of plasma are required daily in the USA as of January 2022. As a result, the growing need for blood transfusion is stimulating the sickle cell disease treatment market’s growth. For the Sickle Cell Disease Treatment Market, a key driving factor is the rise in blood and bone marrow transplantation, leading to advancements in treatments for this disease. The process entails the substitution of unwell blood-forming cells with healthy ones, making it highly beneficial in curing sickle cell diseases and cancers. The goal of a bone marrow transplant is to supplant unhealthy bone marrow, which has been treated to discard the defective cells, with healthy marrow cells. These replacement cells can be either autologous (from the patient’s body) or allogenic (from a donor’s body). The National Transplant Organization (ONT) in Spain reported in June 2024 that Spain registered an 8% increase in its Bone Marrow Donor Registry, reaching a total of 23,686 donors in 2023, and performed a record 3,717 hematopoietic stem cell transplants, equivalent to 77.4 transplants per million population. This rising trend in blood and bone marrow transplants is projected to invigorate the sickle cell disease treatment market.

What key areas define the segmentation of the global sickle cell disease treatment Market?

The sickle cell disease treatment market covered in this report is segmented –

1) By Treatment Modality: Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant

2) By Disease Type: Sickle Cell Anemia, Hemoglobin Sickle C Disease (HbSC), Other Disease Types

3) By Route Of Administration: Oral, Parenteral

4) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Blood Transfusion: Regular Blood Transfusion, Exchange Transfusion

2) By Pharmacotherapy: Hydroxyurea, L-Glutamine, Voxelotor, Crizanlizumab

3) By Bone Marrow Transplant: Allogeneic Transplant, Autologous Transplant

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13048&type=smp

What are the top market players propelling the growth of the sickle cell disease treatment industry?

Major companies operating in the sickle cell disease treatment market are Sun Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Silver Lake Research Corporation0.45, Global Blood Therapeutics Inc., Acceleron Pharma Inc., Sangamo Therapeutics Inc., Medunik USA Inc., Zydus Cadila Healthcare Ltd., Graphite Bio Inc., Addmedica, Emmaus Medical Inc., Bluebird bio Inc., CRISPR Therapeutics AG, GlycoMimetics Inc., Arena Pharmaceuticals Inc., Mast Therapeutics Inc.

What are the key trends shaping the future of the sickle cell disease treatment market?

Leading firms in the market for sickle cell disease treatments are striving to create new oral suspension medicines to enhance patient compliance, augment the effectiveness of the drug, and offer easier treatment methods, particularly for pediatric and elderly patients. Oral suspension drugs are medications in liquid form that contain solid particles, designed to simplify the swallowing process, especially for children or individuals having difficulty with pill ingestion. For example, in March 2024, a company originating from India, Akums Drugs and Pharmaceuticals Ltd., specializing in pharmaceutical preparation manufacturing, introduced a Hydroxyurea oral suspension that remains stable at room temperature. This affordable, room-temperature-stable sickle cell disease treatment aims to boost accessibility in India. With a cost less than 1% of imported equivalents, it provides exact dosage administration via oral syringes, which benefits patients of all ages without the necessity for cold storage.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13048

What regions are dominating the sickle cell disease treatment market growth?

North America was the largest region in the sickle cell disease treatment market in 2024. The regions covered in sickle cell disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Blood And Blood Components Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-and-blood-components-global-market-report

Blood Collection Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-collection-devices-global-market-report

Blood Culture Tests Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-culture-tests-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: